Pharmacokinetics of Non-Psychotropic Phytocannabinoids DOI Creative Commons

Mariana Lacerda,

Andreia Carona,

Sara Castanheira

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 236 - 236

Published: Feb. 12, 2025

Cannabinoids are widely recognized for their potential therapeutic effects, making them significant and valuable candidates medical research applications across various fields. This review aims to analyze the pharmacokinetics of Cannabidiol (CBD), Cannabigerol (CBG), Cannabichromene (CBC), along with corresponding acidic forms, Cannabidiolic acid (CBDA), Cannabigerolic (CBGA), Cannabichromenic (CBCA). Among these cannabinoids, CBD is most extensively studied. Nevertheless, involving all mentioned cannabinoids has shown that pharmacokinetic parameters highly variable, depending significantly on factors such as dose, formulation, route administration, diet. Furthermore, challenges brain penetration first-pass metabolism have been highlighted. In conclusion, this demonstrates progress in understanding non-psychotropic cannabinoids. However, it also underscores need further research, particularly CBG, CBC, respective gap being clinical investigations. Expanding studies essential facilitate optimized use treatments.

Language: Английский

Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial DOI Creative Commons
Carrie Cuttler, Amanda Stueber, Ziva D. Cooper

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: July 13, 2024

Abstract Cannabigerol (CBG) is a phytocannabinoid increasing in popularity, with preclinical research indicating it has anxiolytic and antidepressant effects. However, there are no published clinical trials to corroborate these findings humans. The primary objective of this study was examine acute effects CBG on anxiety, stress, mood. Secondary objectives were whether produces subjective drug or motor cognitive impairments. A double-blind, placebo-controlled cross-over field trial conducted 34 healthy adult participants. Participants completed two sessions (with one-week washout period) via Zoom. In each, they provided ratings mood, prior double-blind administration 20 mg hemp-derived placebo tincture (T0). These collected again after participants ingested the product an online survey (T1), Trier Social Stress Test (T2), verbal memory test DRUID impairment app (T3). Relative placebo, significant main effect overall reductions anxiety as well stress at T1. also enhanced relative placebo. There evidence impairment. may represent novel option reduce adults.

Language: Английский

Citations

6
Pharmacokinetics of Non-Psychotropic Phytocannabinoids DOI Creative Commons

Mariana Lacerda,

Andreia Carona,

Sara Castanheira

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 236 - 236

Published: Feb. 12, 2025

Cannabinoids are widely recognized for their potential therapeutic effects, making them significant and valuable candidates medical research applications across various fields. This review aims to analyze the pharmacokinetics of Cannabidiol (CBD), Cannabigerol (CBG), Cannabichromene (CBC), along with corresponding acidic forms, Cannabidiolic acid (CBDA), Cannabigerolic (CBGA), Cannabichromenic (CBCA). Among these cannabinoids, CBD is most extensively studied. Nevertheless, involving all mentioned cannabinoids has shown that pharmacokinetic parameters highly variable, depending significantly on factors such as dose, formulation, route administration, diet. Furthermore, challenges brain penetration first-pass metabolism have been highlighted. In conclusion, this demonstrates progress in understanding non-psychotropic cannabinoids. However, it also underscores need further research, particularly CBG, CBC, respective gap being clinical investigations. Expanding studies essential facilitate optimized use treatments.

Language: Английский

Citations

0